Bronchial asthma

Active Ingredient: Metaproterenol

Indication for Metaproterenol

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Curative procedure

For this indication, competent medicine agencies globally authorize below treatments:

20 mg 3-4 times daily

For:

Dosage regimens

Oral, 20 milligrams metaproterenol, 3 to 4 times daily.

Detailed description

20 mg t.i.d. or q.i.d.

Dosage should be individualized, and patient response should be monitored by the prescribing physician on an ongoing basis.

If a previous effective dosage regimen fails to provide the usual relief, medical advice should be sought immediately as this is a sign of seriously worsening asthma that requires reassessment of therapy.

In accordance with the present practice for asthma treatment, concomitant anti-inflammatory therapy should be part of the regimen when a β2-agonist needs to be used on a regular daily basis.

10 mg 3 times daily

For:

Dosage regimens

In case that patient age in years is ≥ 4 and patient age in years is ≤ 12, oral, 10 milligrams metaproterenol, 3 times daily.

Detailed description

For patients 4-12 years old 10 mg 3 times daily.

Dosage should be individualized, and patient response should be monitored by the prescribing physician on an ongoing basis.

If a previous effective dosage regimen fails to provide the usual relief, medical advice should be sought immediately as this is a sign of seriously worsening asthma that requires reassessment of therapy.

In accordance with the present practice for asthma treatment, concomitant anti-inflammatory therapy should be part of the regimen when a β2-agonist needs to be used on a regular daily basis.

20 mg 3 times daily

For:

Dosage regimens

Oral, 20 milligrams metaproterenol, 3 times daily.

Detailed description

Above 12: 20 mg (10 mL) t.i.d.

Dosage should be individualized, and patient response should be monitored by the prescribing physician on an ongoing basis.

If a previous effective dosage regimen fails to provide the usual relief, medical advice should be sought immediately as this is a sign of seriously worsening asthma that requires reassessment of therapy.

In accordance with the present practice for asthma treatment, concomitant anti-inflammatory therapy should be part of the regimen when a β2-agonist needs to be used on a regular daily basis.

Active ingredient

Metaproterenol

Orciprenaline sulphate is a bronchodilating agent. The bronchospasm associated with various pulmonary diseases-chronic bronchitis, pulmonary emphysema, bronchial asthma, silicosis, tuberculosis, sarcoidosis and carcinoma of the lung, has been successfully reversed by therapy with orciprenaline sulphate.

Read more about Metaproterenol

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.